Open an account

Vaccinex

VCNX · OTC

$0.7001−$0.2999 (−29.99%)TodayMarket closed ·
No price history for this range.

About VCNX

Vaccinex, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Rochester, New York and currently employs 23 full-time employees. The company went IPO on 2018-08-09. The firm is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including neuroinflammatory and neurodegenerative diseases and cancer. The company also discovered VX5 using its ActivMAb platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of autoimmune disorders.

Employees
23
Headquarters
Rochester, New York
Listed
Aug 9, 2018
Sector
Health Care
Industry
Biotechnology
Website
vaccinex.com

VCNX key statistics

Market cap
2.69M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
622
Volume
203
Open price
$0.7001
High today
$0.7001
Low today
$0.7001
52 Week high
$1.50
52 Week low
$0.31

Vaccinex (VCNX) at a glance

Vaccinex (VCNX) last traded at $0.7001, with a market cap of 2.69M and a price-to-earnings ratio of 0.00.

Volume so far is 203 shares, below the average of 622 shares a day.

Over the past year Vaccinex has ranged from $0.31 to $1.50, and now sits 33% of the way up that range.

Vaccinex met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY23 it reported -$1.09 per share against an estimate of $0.00.

VCNX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 24.2% on average.

  1. Q1 FY20: reported -$94.50 per share against an estimate of -$160.65
  2. Q2 FY20: reported -$81.90 per share against an estimate of -$109.24
  3. Q3 FY20: reported -$92.40 per share against an estimate of -$93.18
  4. Q4 FY20: reported -$60.48 per share against an estimate of -$80.32
  5. Q2 FY21: reported -$44.10 per share against an estimate of -$62.12
  6. Q1 FY23: reported -$0.10 per share against an estimate of $0.00
  7. Q2 FY23: reported -$0.12 per share against an estimate of $0.00
  8. Q3 FY23: reported -$1.09 per share against an estimate of $0.00

VCNX news

  • Vaishali Prayag

    Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock?

  • Avi Kapoor

    Crude Oil Down Over 1%; US Industrial Production Declines In November

  • Avi Kapoor

    Dow Dips Over 200 Points; US Retail Sales Top Estimates

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Dylan Berman

    What's Going On With Vaccinex Stock Wednesday?

  • Avi Kapoor

    Around $3M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying

  • Avi Kapoor

    Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket

Similar companies

Companies in the same industry as Vaccinex

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.